Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.

Also called NCT03159052

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 450 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03159052
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03159052. Randomized; quadruple masking; primary purpose treatment. Start 2017-06 (anticipated); primary completion 2018-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
SHR3824
Intervention (Drug)
Placebo
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03159052
Content hash
c9baa972d92c488dd21df273105f770f4ce919617730dcfdbc61bbaf0f066dbb